Related Experiment Video
Updated: Jun 21, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy
Shilen Lakhani1, Lev Davidson, Dennis A Priebat
1Section of Gastroenterology and Hepatology, Washington Hospital Center, Georgetown University School of Medicine, 110 Irving Street NW, Washington, DC, 20010, USA.
Imatinib (Gleevec, Novartis), an inhibitor of BCR-ABL, platelet-derived growth factor, and KIT receptor tyrosine kinases, is widely used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. We describe a case of activation of chronic hepatitis B infection associated with imatinib therapy.
Imatinib (Gleevec, Novartis), an inhibitor of BCR-ABL, platelet-derived growth factor, and KIT receptor tyrosine kinases, is widely used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. We describe a case of activation of chronic hepatitis B infection associated with imatinib therapy.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Inhibitors of Viral Protein Synthesis
Chronic Pancreatitis II: Collaborative Care
Assessment:
